Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04861155
Other study ID # SIVA-PS1
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 22, 2021
Est. completion date October 26, 2021

Study information

Verified date November 2021
Source Evoleen AG
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

When diagnosing chronic cough (cough lasting longer than 8 weeks), the physician nowadays very often relies on the patient's narrative and description. In our research project we want to find out whether a cough detector can continuously and reliably record the cough, how the user-friendliness of the cough detector is assessed and whether this continuous recording can support the physician in his diagnosis.


Description:

After chronic cough diagnosis, the Principal Investigator (or his designee) will identify patients who are potentially eligible to participate in this pilot study, based on the predefined inclusion criteria. A number of 25 participants will be recruited for this pilot study: 10 suffering from chronic cough with unclear underlying cause, 4-6 suffering from COPD, 4-6 suffering from Asthma and 4-6 suffering from interstitial lung disease. Patients who choose to participate will be entered into the pilot study after obtaining their informed consent, when they will receive the SIVA-P3 wearable (and charging device), helped to download the SIVA-P3 smartphone application and couple the wearable component with the smartphone. Furthermore, they will be asked to rate their current cough severity on a visual analog scale (Cough Severity VAS). Participants will receive an envelope with a second Cough Severity VAS and a return envelope to send back the SIVA-P3 wearable and charging device at the end of the study. Participants will receive standard care and will be asked to wear the wearable component during the day, charge it on the bedside while sleeping and to otherwise go about daily life as they would do normally for a duration of seven days. In the evening of every day, they will be prompted by the SIVA-P3 smartphone application to indicate the timing of their main meals. On day 8, the study nurse will conduct a pre-scheduled phone interview with each participant. The phone interview will include instructing the patient to fill in the final Cough Severity VAS, asking the questions of the Participant User Feedback Questionnaire, and instructing the patient to send the Cough Severity VAS form and the SIVA-P3 wearable (and charging device) back to the trial site using the return envelope. The Participant User Feedback Questionnaire will include ratings of wearing comfort, usability and likeliness to wear for extended period of time.


Recruitment information / eligibility

Status Completed
Enrollment 29
Est. completion date October 26, 2021
Est. primary completion date October 26, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Informed Consent as documented by signature - Men and women, aged 18 and over at date of signing the Informed Consent Form - Patients diagnosed with a chronic cough of unknown origin or COPD or Asthma or with interstitial lung disease. - Attending the treatment procedure as an outpatient - Using a smartphone (minimal version: iOS 13 / Android 10) on a daily basis and willing to install SIVA-P3 smartphone application - Adequate communication in German or Swiss-German (all study documentation and SIVA-P3 will be set to German language only). Exclusion Criteria: - Unable to make the decision to participate in a clinical study (e.g. seriously ill or unconscious subject, or subject with a mental or intellectual disability) - Inability to follow the procedures of the study, e.g. due to physical or intellectual impairment precluding informed consent or protocol adherence, psychological disorders (excluding depression) or dementia - Use of any other medical device equipment (e.g. portable oxygen concentrator, artificial cardiac pacemaker, implantable cardioverter-defibrillator) - Pregnancy: Female participants in child-bearing age without a negative pregnancy test (urine test). Female participants who are neither surgically sterilized / hysterectomized nor post-menopausal for longer than 2 years are considered as being of childbearing potential.Known or suspected non-compliance, drug or alcohol abuse - Participation in another clinical study

Study Design


Related Conditions & MeSH terms


Intervention

Device:
SIVA-P3
Digital cough recording: Participants receive a small, wearable data recorder, wear it during waking hours and keep it on the nightstand during sleep for 7x24 hours. The data is sent to a smartphone application, where a cough detection algorithm converts it into time-stamped cough events. Participants respond to questions on their smartphone once a day for additional context data. The cough events and context data are sent to a secure online database for further evaluation. For the first 24 hours, segments of audio data are sent to be able to validate the performance of the cough detection algorithm. Afterwards, only cough events and context data are sent from the participant's smartphone.

Locations

Country Name City State
Switzerland University Hospital Zurich Zurich

Sponsors (2)

Lead Sponsor Collaborator
Evoleen AG University Hospital, Zürich

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Validation The primary outcomes are sensitivity, specificity and related metrics (positive and negative predictive values, rates of false positive and false negative detections per hour) for cough frequency measurement of SIVA-P3 in the target patient population over a 24-hour validation phase (first 24 hours after baseline visit). Sensitivity, specificity and positive and negative predictive values contribute to a description of cough monitor performance. 24 hours
Secondary Wearing Time The wearable device continuously records movement data. This movement data is used to determine if the wearable device is being worn. 7 days
Secondary Wearing Comfort Wearing Comfort will be determined through quantitative analysis of closed and open questions in the Participant User Feedback Questionnaire. 7 days
Secondary Awareness of wearing the device Patients will be questioned via the smartphone application how many times they have approximately noticed during the day that they have been wearing the device. 7 days
Secondary Usability Usability from the patient's perspective will be determined through quantitative analysis of closed questions in the Participant User Feedback Questionnaire. 7 days
Secondary Continued Wearing Likeliness Continued Wearing Likeliness will be determined through quantitative analysis of closed and open questions in the Participant User Feedback Questionnaire. 7 days
Secondary Correlation of patient-reported cough severity Cough Severity Correlation will be determined by correlating daily cough counts determined by the SIVA-P3 algorithm with the patient's self-reported Cough Severity VAS. 7 days
Secondary Variations of time course of coughing between different days within individual patients To compare the variations of time course of coughing, the hourly profiles of each day will be interpreted as discrete distribution functions. A range of statistical features associated with properties of distributions will be calculated for all profiles and compared both within individual patients and across the whole population. These features will include mean, median, variance, skewness, kurtosis and additional descriptive statistics for multimodal distributions. 7 days
Secondary Diagnostic prediction models To evaluate the predictive performance of a mathematical model, different models will be explored. The outcome is the performance of the best predictive model identified. 7 days
See also
  Status Clinical Trial Phase
Completed NCT01432730 - A Study to Assess the Efficacy of Gefapixant (MK-7264/AF-219), in Participants With Chronic Cough (MK-7264-006) Phase 2
Not yet recruiting NCT01413698 - Cough Count Validation N/A
Completed NCT03639727 - Cough in Eastern and Central Finland N/A
Completed NCT03696108 - A Study of Gefapixant (MK-7264) in Japanese Adult Participants With Refractory or Unexplained Chronic Cough (MK-7264-038) Phase 3
Recruiting NCT03638063 - ATP and Capsaicin Cough Provocation Test in Chronic Cough and Bronchiectasis
Recruiting NCT06376448 - An Observational Study Using Novel Questionnaire to Characterize Cough Phenotypes in Patients With Chronic Cough
Completed NCT03172130 - Sham CPAP vs. Straight CPAP for Chronic Cough N/A
Recruiting NCT06286163 - Neuroinflammatory Interactions of ATP and P2X3 Receptor in the Airways of Chronic Cough Patients
Completed NCT03622216 - A Dose Escalation Study of Bradanicline in Refractory Chronic Cough Phase 2
Recruiting NCT05522699 - Cough Suppressive Therapy in Patients With Chronic Cough N/A
Completed NCT01297790 - Cough Responses to Tussive Agents in Health and Disease N/A
Completed NCT04193202 - Efficacy and Safety of Gefapixant (MK-7264) in Adult Participants With Recent Onset Chronic Cough (MK-7264-043) Phase 3
Completed NCT01865422 - French Linguistic and Metric Validations of Parent-proxy QOL Chronic Cough Specific Questionnaire (PC-QOL) N/A
Completed NCT04525885 - A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-030)-China Extension Phase 3
Completed NCT04193176 - Efficacy and Safety of Gefapixant (MK-7264) in Women With Chronic Cough and Stress Urinary Incontinence (MK-7264-042) Phase 3
Recruiting NCT05362097 - Analysis of the Reliability and Validity of the Chinese Version of CC-QoL
Recruiting NCT03787511 - Chronic Cough and Small Fiber Neuropathy N/A
Terminated NCT03864328 - A Phase 2b Study of Inhaled RVT-1601 for the Treatment of Persistent Cough in IPF Phase 2
Completed NCT05274516 - A Trial of HRS-2261 in Healthy Subjects After Single and Multiple Oral Administration Phase 1
Not yet recruiting NCT01807832 - The Use of Capsaicin Challenge for Diagnosis, Monitoring and Follow-up of Chronic Cough. N/A